Drugmakers decry German pricing proposals; EMEA: No safety concerns on contaminated Rotarix;

@FiercePharma: Pharma M&A: 10 years, 1,345 deals, $694B. Article | Follow @FiercePharma

> German Health Minister Phillip Rosler's proposed package of pharma-pricing reforms includes an increase in the mandatory discount for patented drugs from the current 6 percent to 16 percent, and the plan freezes prices at August 2009 levels until the end of 2013. Report

> The European Medicines Agency says it saw no safety concerns with GlaxoSmithKline's Rotarix vaccine, which had been contaminated with an apparently harmless pig virus. Report

> A group of outside experts will scrutinize the World Health Organization's response to the swine flu outbreak and likely examine whether the term pandemic was appropriate for what has turned out to be a relatively mild disease. Report

> AstraZeneca bought back 1 million of its shares at 2993 pence per share, leaving 1.45 billion shares still trading. Report

> KV Pharmaceutical doesn't expect to resume shipments of its products until the fourth quarter of this calendar year at the earliest. Report

> Merck KGaA says its Erbitux tumor-fighting drug was approved for wider use in Japan as a first-line treatment for people with colon cancer who carry the KRAS wildtype gene. Report

> The pandemic H1N1 influenza virus can develop resistance to the commonly used antiviral drugs much faster than expected, federal researchers say. Report

> Drugmaker Eli Lilly spent $2.2 million in the fourth quarter of 2009 lobbying the federal government on intellectual property rights, anti-counterfeiting measures and healthcare reform. Report

Biotech News

 @FierceBiotech: VCs eager to invest in obesity-focused startups. Article | Follow @FierceBiotech  

@JohnCFierce: In a frank assessment, Antisoma CEO suggests the 404 cancer program is kaput. Novartis doing a review, unlikely to pay out any new cash. | Follow @JohnCFierce

> Antisoma shares crater as lead cancer drug flunks Phase III. Report

> "Wow": Developers prepare to reap rewards from biotech R&D tax credit. Article

> Harlan Waksal backs a fledgling cancer drug developer. Article

> Analysts ponder soaring Arca shares. Story

 > Avila teams with Leukemia & Lymphoma Society on early-stage cancer trial. Report

 > GSK looks to Japan for new biotech deals. Article

Biotech IT News

> Trial recruiter scans Craigslist personals for HIV subjects. Report

> Pharma IT spend is on the rise. Report

> Experts: Beware of breaches in cloud computing. Item

> Cadence to file with FDA using electronic gateway. Story

And Finally... The majority of nitroglycerin drugs sold last year had not been approved, FDA says. Report